BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SCV-07: Phase IIb started

SciClone began a double-blind, placebo-controlled Phase IIb trial to evaluate 0.1, 0.3 and 1 mg/kg doses of daily subcutaneous SCV-07 for 7 weeks in 160 patients with head and neck cancer...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >